{"paper_id":"9f71598b-f919-41fc-bff2-f85fac22ab07","body_text":"Notes\nThis profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.\nReferences\nPraecis Pharmaceuticals Incorporated. Praecis Pharmaceuticals Incorporated announces FDA priority review and filing of its abarelix depot NDA for prostate cancer. Media Release: [2 pages], 25 Jan 2001\nPraecis Pharmaceuticals Incorporated. PRAECIS PHARMACEUTICALS INCORPORATED Announces Resubmission of Plenaxis NDA. Media Release: 26 Feb 2003. Available from URL: http://www.praecis.com\nPraecis Pharmaceuticals Incorporated. PRAECIS PHARMACEUTICALS INCORPORATED Presents Results from Clinical Trial of Plenaxis in Advanced, Symptomatic Prostate Cancer Patients. Media Release: 6 Feb 2003. Available from URL: http://www.praecis.com\nMenon M, Glode LM, Martin K, et al. Abarelix (PPI-149), a novel and potent GnRH antagonist, induces a rapid and profound reduction in testosterone and PSA in advanced prostate cancer patients. Journal of Urology 159 (Suppl): 334, May 1998\nWong SL, Dmowski WP, DePaoli A, et al. Comparative pharmacodynamic effects of abarelix depot-F vs. lupron Depot(Rm) in women with endometriosis-associated pain. Fertility and Sterility 74 (Abstr. Suppl.): 118, Sep 2000\nBowser A. Abarelix ablates testosterone production in prostate cancer. Inpharma 1152: 9–10, 29 Aug 1998\nGarnick MB, Tomera K, Campion M, et al. Abarelix-depot — a sustained-release formulation of a potent GnRH pure antagonist in patients with prostate cancer: initial clinical results and endocrine comparison with superantagonists Lupron(R) and Zoladex(R). Ninth International Congress on Anti-Cancer Treatment: 180, 2 Feb 1999\nGarnick MB, Tomera K, Campion M, et al. Abarelix-depot, a sustained-release formulation of a potent GnRH pure antagonist in patients with prostate cancer: phase II clinical results and endocrine comparison with superagonists Lupron(Rm) and Zoladex(Rm). Journal of Urology 161 (Suppl.): 340, Apr 1999\nGarnick MB, Campion M, Kuca B, et al. PSA kinetics: rates of decline are significantly more rapid following therapy with the GnRH antagonist abarelix-depot, compared to superagonists Lupron(Rm) and Zoladex(Rm) in prostate cancer patients. Journal of Urology 161 (Suppl.): 98, Apr 1999\nFair WR, Garnick M, Abarelix-Depot Study Group. Abarelix depot vs. Leuprolide acetate +/− Bicalutamide, for patients with prostatic cancer: combined results in multi-institutional, randomized, phase III studies in 526 patients. BJU International 86 (Suppl. 3): 219, Nov 2000\nTrachtenberg J, Gittelman M, Steidle C, et al. Abarelix-Depot versus leuprolide acetate plus bicalutamide [Casodex], for prostate cancer: results of a multi-institutional, randomized, phase III study in 255 patients. 36th Annual Meeting of the American Society of Clinical Oncology 19: 332, 20 May 2000\nTrachtenberg J, Gittleman M, Steidle C, et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. Journal of Urology 167: 1670–1674, Apr 2002\nAmgen Inc. Amgen, Praecis say abarelix data shows serum PSA drop. Media Release: [7 pages], 4 Jun 2001. Available from URL: http://www.amgen.com\nGaylis F, Woolley J, Garnick MB, et al. The economic value of abarelix depot therapy in highly symptomatic prostate cancer patients. 37th Annual Meeting of the American Society of Clinical Oncology 20: 162, Part 2, 12 May 2001\nMartha PM, Gray ME, Campion M. et al. Abarelix-depot, a potent pure GnRH antagonist, rapidly induced sustained suppression of the pituitary-gonadal axis in women with endometriosis. Fertility and Sterility 71 (Suppl. 1): 9, Apr 1999\nPraecis Pharmaceuticals Corporation. PRAECIS PHARMACEUTICALS INCORPORATED Announces Preliminary Results of Phase II/III Study of Plenaxis for the Treatment of Endometriosis. Media Release: 19 Jun 2002. Available from URL: http://www.praecis.com\nRights and permissions\nAbout this article\nCite this article\nAbarelix. Drugs R&D 4, 161–166 (2003). https://doi.org/10.2165/00126839-200304030-00004\nPublished:\nIssue date:\nDOI: https://doi.org/10.2165/00126839-200304030-00004","source_license":"public-domain-us","license_restricted":false}